
Parkinson Disease
Latest News
Latest Videos

CME Content
More News

Phase 1b trials involving patients with Parkinson are planned for late 2024, with data expected by mid-2025.

The panelists provided clinical insight on the utilization of IPX203, its potential benefits and clinical implications, as well as the practicalities of transitioning patients from other therapies.

The panelists discussed the safety profile of IPX203, considering challenges with transitioning, dosing strategies, and monitoring and adjusting patients’ individual dosage.

Dr. Hauser and Dr. Fernandez provided insight on the body of supportive evidence for IPX203, the notable takeaways from RISE-PD, and the long-term benefits observed from treated patients.

IPX203 combines immediate and extended-release levodopa, utilizing advanced delivery technology to optimize absorption and prolong therapeutic effects in patients with Parkinson disease.

Medtronic's asleep DBS approval could expand treatment options for patients unable to tolerate awake surgery, enhancing access to deep brain stimulation therapy.

In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.

Marketed as Crexont, the combination extended- and immediate-release treatment is indicated for treatment of PD, and is anticipated to be available in the United States in September 2024.

Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.

Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.

Steve Hoffmann, MS, and Alessio Travaglia, PhD, provide commentary on a recently launched public-private partnership aimed at identifying biomarkers to better differentiate Parkinson disease from other related neurodegenerative disorders.

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

The investigational therapy, which targets neurodegeneration, has shown promise in phase 2 and 3 studies of Alzheimer disease and Parkinson disease, with additional studies on the way.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]

Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

Most treatment-emergent adverse events for patients on UB-312 were mild or moderate, and comparable to placebo.

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]

The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about making strides in developing minimally invasive tests and imaging ligands for neurodegenerative diseases, such as Parkinson disease. [WATCH TIME: 2 minutes]

The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]

Over the 3-year treatment period, buntanetap resulted in improvements in motor and nonmotor functions in patients with postural instability and gait difficulty, a group with faster disease progression.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute provided an in-depth explanation of how the Syn-One test is used to help detect patients with Parkinson disease and related disorders. [WATCH TIME: 5 minutes]